Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing.

Samira Kiani, an ASU assistant professor who co-led the study, told BioCentury she believes her group is the first to demonstrate that the approach of removing some immunogenic epitopes could alleviate cellular immunity against Cas9...